PURPOSE: Periprostatic brachytherapy doses impact biochemical control.
In this study, we evaluate extracapsular volumetric dosimetry following permanent prostate brachytherapy in patients entered in a multi-institutional community database.
MATERIAL AND METHODS: In the database, 4547 patients underwent brachytherapy (3094 - 125I, 1437 - 103Pd and 16 - 131Cs). Using the originally determined prostate volume, a 5 mm, 3-dimensional peri-prostatic anulus was constructed around the prostate (except for a 2 mm posterior margin), and evaluated in its entirety and in 90° segments. Prostate dosimetric parameters consisted of a V100 and D90 while the annular dosimetry was reported as a V100.
RESULTS: The intraprostatic V100 and D90 for 103Pd, and 125I were statistically comparable when stratified by isotope and/or monotherapy vs. boost. The overall mean V100 for the periprostatic annulus was 62.8%. The mean V100 at the base (51.6%) was substantially less than the apex (73.5%) and midgland (65.9%). In addition, for all patients, the anterior V100 (45.7%) was less than the lateral (68.8%) and the posterior (75.0%). The geometric V100 annular differences were consistent when evaluated by isotope. Overall, the V100 was higher in the 125I cohort.
CONCLUSIONS: The optimal extracapsular brachytherapy dose and radial extent remains unknown, but will prove increasingly important with reductions and/or elimination of supplemental external beam radiation therapy. The large multi-institutional community database demonstrates periprostatic annular doses that are not as robust as those in selected high volume brachytherapy centers, and may be inadequate for optimal biochemical control following monotherapeutic brachytherapy, especially in higher risk patients.
Written by:
Merrick GS, Butler WM, Grimm P, Morris M, Lief JH, Bennett A, Fiano R. Are you the author?
Schiffler Cancer Center & Wheeling Jesuit University, Wheeling WV.
Reference: J Contemp Brachytherapy. 2013 Sep;5(3):117-21.
doi: 10.5114/jcb.2013.37941
PubMed Abstract
PMID: 24143144
UroToday.com Prostate Cancer Section
